Novo's dark forecasts have been disproved: "We're stronger in the US than we've been in many years"

Danish pharmaceutical company Novo Nordisk's largest single market business has proven – in record time – to be stronger than the firm expected.

Novo Nordisk CEO Lars Fruergaard Jørgensen. | Photo: Stine Bidstrup/ERH

Novo Nordisk has refuted skepticism and successfully led its US business to provide even better results than the pharmaceutical company had otherwise dared hope.

Now, Novo Nordisk has far surpassed its so-called "strategic aspirations," which replaced its long-term financial goals in late 2019.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs